AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for syst
AstraZeneca is awarding grants from its Connections for Cardiovascular Health programme to non-profit organisations that address the challenges of preventing and controlling cardiovascular disease by conducting programmes for at-risk groups.